期刊
JOURNAL OF VIROLOGY
卷 81, 期 7, 页码 3645-3648出版社
AMER SOC MICROBIOLOGY
DOI: 10.1128/JVI.01778-06
关键词
-
类别
资金
- NIAID NIH HHS [R21 AI 071265-01] Funding Source: Medline
- NIGMS NIH HHS [P01 GM056550, P01 GM 056550-08] Funding Source: Medline
- NINDS NIH HHS [R21 NS047970] Funding Source: Medline
- NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000883, Z01AI000887] Funding Source: NIH RePORTER
- NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM056550] Funding Source: NIH RePORTER
- NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R21NS047970] Funding Source: NIH RePORTER
The AIDS epidemic continues to spread at an alarming rate worldwide, especially in developing countries. One approach to solving this problem is the generation of anti-human immunodeficiency virus (HIV) compounds with inhibition spectra broad enough to include globally prevailing forms of the virus. We have examined the HIV type 1 (HIV-1) envelope specificity of a recently identified entry inhibitor candidate, UNG-105, using surface plasmon resonance spectroscopy and pseudovirus inhibition assays. The combined results suggest that the HNG-105 molecule may be effective across the HIV-1 subtypes, and they highlight its potential as a lead for developing therapeutic and microbicidal agents to help combat the spread of AIDS.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据